The Potassium Problem in Hemodialysis: Interprofessional Approaches to Hyperkalemia Management in ESRD
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.
Supported through an independent educational grant from AstraZeneca.
Specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants.
- Describe the pathophysiology of hyperkalemia in end stage renal disease (ESRD), especially in patients receiving hemodialysis, and discuss the immense morbidity and mortality implications of elevated predialysis K+ levels.
- Review traditional strategies for managing serum K+ in ESRD patients receiving dialysis and identify the pivotal shortcomings of these standard approaches.
- Examine novel pharmacologic treatment approaches for reducing the incidence of predialysis hyperkalemia, including an appraisal of completed and ongoing clinical trials and recent FDA approvals.
- Using a case-based format, apply evolving, interprofessional management strategies to prevent and manage hyperkalemia in ESRD patients receiving hemodialysis, with a focus on the promising role of K+ binders.
5 min Welcome and Introductions/Pre-test
10 min Hyperkalemia in Hemodialysis: Pathophysiology, Risk Factors, and Clinical Gravity
20 min A Paradigm Evolved: The Emerging Role of K+ Binders in End Stage Renal Disease
20 min Meeting Complexity with Collaboration: A Team-based Approach for Managing K+ in Dialysis Patients
5 min Conversations with the Experts/Q&A/Post-test
Csaba P. Kovesdy, MD
Fred Hatch Professor of Medicine
Director, Clinical Outcomes and Clincial Trials Program
Division of Nephrology, University of Tennessee Health Science Center
Nephrology Section Chief, Memphis VA Medical Center
Dr. Kovesdy obtained his MD degree in Hungary, and he completed his Internal Medicine Residency at the Henry Ford Hospital in Detroit, MI, and his Nephrology Fellowship at the Johns Hopkins Bayview Medical Center in Baltimore, MD. Dr. Kovesdy is Board Certified in Internal Medicine and in Nephrology.
His research interests are centered among others on epidemiology and outcomes, cardiovascular risk factors, metabolic abnormalities, race-ethnicity, and bone and mineral disorders in pre-dialysis chronic kidney disease. He is Principal Investigator on several studies and federal grants in these areas. He has published his research in over 500 peer-reviewed articles, as well as numerous abstracts and book chapters.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a
commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their
spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity
producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a
commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be
of potential importance to their evaluation of a presentation.
Estella Davis, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Csaba P. Kovesdy, MD–has disclosed that he is a consultant for AstraZeneca, Bayer, Cara Therapeutics, Reata, Takeda, and Tricida; receives
grant/research support from Relypsa.
Barbara Odom BSN, RN, CDN–has no relevant financial relationships to disclose in relation to the content of this activity.
George Bakris, MD–has disclosed that he is a consultant for Alynlam, AstraZeneca, Bayer, Ionis, Merck, Novo-Nordisk, Janssen, Relypsa, and Vifor; receives
grant/research support from Novo Nordisk and Vascular Dynamics.
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP–has disclosed that she receives grant/research support from Vifor.
Csaba P. Kovesdy, MD– has disclosed that he is a consultant for AstraZeneca, Bayer, Cara Therapeutics, Reata, Takeda, and Tricida; receives grant/research
support from Relypsa.
Matthew R. Weir, MD–has disclosed that he is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, and Vifor.
Terri Cook, PharmD, BCPC, AACC–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Barry Wall, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-21-001-L01-P)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation